Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2026

Imported from official source

Announcement

Safety Classified by Officially

Seven new medicines recommended for approval

EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its November 2026 meeting.

The committee recommended granting a marketing authorisation for Aumseqa (aumolertinib), for the treatment of non-small cell lung cancer.

The CHMP recommended granting a marketing authorisation for Baxfendy (baxdrostat), for the treatment of insufficiently controlled hypertension.

Zybrivo (sintilimab) received a positive opinion from the CHMP for the treatment of non-squamous non-small cell lung cancer in adults.

The committee adopted positive opinions for two biosimilar medicines, Garzulys (insulin aspart) and Donrafylix (insulin aspart), for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Two generic medicines received a positive opinion:

  • Fondaparinux sodium Evumed (fondaparinux sodium), for the prevention of venous thromboembolic events, and the treatment of deep vein thrombosis, pulmonary embolism, unstable angina and myocardial infarction in adults.
  • Ruxolitinib Krka (ruxolitinib), for the treatment of myelofibrosis and polycythaemia vera in adults, and treatment of Graft-versus-host disease in adults and children.
  • Recommendations on extensions of therapeutic indication for 11 medicines

    The CHMP recommended extending the use of Gazyvaro (obinutuzumab) to treat adults with moderate-to-severe active systemic lupus erythematosus, an autoimmune disease predominantly affecting women that occurs when the immune system attacks the body’s own tissues, causing inflammation that can damage organs. Gazyvaro addresses needs of patients whose disease is not adequately controlled by standard treatment. It reduces disease activity while allowing patients to reduce their corticosteroid use and the associated risk of side effects. See more details in the news announcement in the grid below.

    This is an extract. The publication continues at the source.

    Source: European Medicines Agency.

    Read the original at the source: https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2026

    Officially imported this from European Medicines Agency’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.

    Provenance

    Organization
    European Medicines Agency — imported from official source
    Official source
    https://www.ema.europa.eu/en/news.xml RSS
    Imported
    November 13, 2026 11:01
    Versions
    1 recorded
    Identity
    https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human...

    Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.